Last reviewed · How we verify
Monovalent OPV 2 week interval
Monovalent OPV 2 week interval is a Biologic drug developed by International Centre for Diarrhoeal Disease Research, Bangladesh. It is currently FDA-approved.
The Monovalent OPV 2 week interval, developed by the International Centre for Diarrhoeal Disease Research, Bangladesh, is a marketed vaccine with a key composition patent expiring in 2028. The vaccine's primary strength lies in its established market presence and specific dosing interval, which may offer logistical advantages in vaccination programs. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic manufacturers.
At a glance
| Generic name | Monovalent OPV 2 week interval |
|---|---|
| Sponsor | International Centre for Diarrhoeal Disease Research, Bangladesh |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine (PHASE4)
- Poliovirus Vaccine Trial in Bangladesh (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Monovalent OPV 2 week interval CI brief — competitive landscape report
- Monovalent OPV 2 week interval updates RSS · CI watch RSS
- International Centre for Diarrhoeal Disease Research, Bangladesh portfolio CI
Frequently asked questions about Monovalent OPV 2 week interval
What is Monovalent OPV 2 week interval?
Who makes Monovalent OPV 2 week interval?
What development phase is Monovalent OPV 2 week interval in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing